Moreover, tesevatinib, an inhibitor of EGFR, HER2, c-SRC, and VEGFR, which reduced cyst growth in autosomal-recessive PKD (ARPKD) mice [10], was recently tested for efficacy and safety in a clinical phase-2 study in ADPKD patients (ClinicalTrials.gov Identifier: NCT03203642). The gene discussed is KDR; the disease is autosomal dominant polycystic kidney disease.